In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Peter Zang, MD
Peter Zang, MD, is a clinical resident/fellow at City of Hope Comprehensive Cancer Center.
Articles by Peter Zang, MD